EUCTR2013-000980-10-ES进行中（未招募）1 期
TOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson?s disease patients with motor complications not well controlled on medical treatment - TOLEDO
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 102
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or female patients aged ?30
- •- Diagnosis of idiopathic Parkinson?s disease of >3 years? duration, defined by the UK Brain Bank criteria (with the exception of >1 affected relative being allowed), without any other known or suspected cause of Parkinsonism
- •- Hoehn & Yahr stage up to 3 in the ON and 2 to 5 in the OFF state
- •- Motor fluctuations not adequately controlled on medical treatment including L-dopa which was judged to be optimal by the treating physician
- •- Average of OFF time>= 3 h/day based on screening and baseline diary entries with no day with < 2 hours of OFF time recorded
- •- Stable medication regimen, with a stable dose of L-dopa administered in at least 4 intakes, for at least 28 days prior to baseline. All oral or transdermal antiparkinsonian drugs are permitted, with the exception of budipine. This regimen may include the use of L-dopa /DDCI rescue medication if this occurs up to 2 times a day, at doses of up to 200 mg L-dopa/day
- •- Patients must be able to differentiate between the ON and OFF state and between troublesome and non-troublesome dyskinesias
- •- Male and female patients must be compliant with a highly effective contraceptive method (oral hormonal contraception alone is not considered highly effective and must be used in combination with a barrier method) during the study and for 9 months long-term follow-up period, if sexually active
- •- Females of childbearing potential must have a negative serum hCG pregnancy test at screening
- •- Ability to accurately complete a paper diary on designated days (with assistance from caregivers, if required), recording periods when they are ?ON without troublesome dyskinesia?, ?ON with troublesome dyskinesia?, OFF, and sleeping
- •- Written informed consent prior to enrolment, after being provided with detailed information about the nature, risks, and scope of the clinical trial as well as the expected desirable and adverse effects of the study treatments
- •- Patients considered reliable and capable of adhering to the protocol, visit schedule, and medication intake according to the judgment of the investigator
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 27
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 75
排除标准
- •- History of respiratory depression
- •- Hypersensitivity to apomorphine or any excipients of the medicinal product
- •- High suspicion of other parkinsonian syndromes
- •- Presence of severe freezing or clinically relevant postural instability leading to falls during the ON state
- •- Concomitant therapy or within 28 days prior to baseline with: apomorphine pen injections, alpha-methyl dopa, metoclopramide, reserpine, neuroleptics, methylphenidate, or amphetamine; intrajejunal L-dopa
- •- Previous use of apomorphine pump treatment
- •- History of deep brain stimulation or lesional surgery for PD
- •- Any medical condition that is likely to interfere with an adequate participation in the study, including e.g. current diagnosis of unstable epilepsy; clinically relevant cardiac dysfunction and/or myocardial infarction or stroke within the last 12 months
- •- Symptomatic, clinically relevant and medically uncontrolled orthostatic hypotension
- •- Patients with a borderline QT interval corrected for heart rate according to Bazett?s formula (QTc) of >450 ms for male and >470 ms for female at Screening or history of long QT syndrome; or >450 ms absolute duration
- •- Clinically relevant hepatic dysfunction (total bilirubin >2.0 mg/dL, ALT and AST >2 times the upper limit of normal)
- •- Clinically relevant renal dysfunction (serum creatinine >2.0 mg/dL);
- •- Pregnant and breastfeeding women
- •- Clinically relevant cognitive decline, defined as MMSE ?24 or according to DSM IV criteria for dementia
- •- Active psychosis or history of at least moderate psychosis in the past year, or with medically uncontrolled severe depression; very mild illusions or hallucinations in the sense of ?feelings of passage or presence? with fully retained insight are not an exclusion criterion
- •- Known history of melanoma
- •- Any investigational therapy in the 4 weeks prior to randomization
- •- History or current drug or alcohol abuse or dependencies
研究者
相似试验
进行中（未招募）
1 期
Clinical trial of apomorphine subcutaneous infusion in patients with advanced Parkinson’s diseaseParkinson Disease (PD) in patients with motor fluctuations not well controlled on medical treatmentMedDRA version: 18.0Level: LLTClassification code 10034006Term: Parkinson's disease aggravatedSystem Organ Class: 100000004852EUCTR2013-000980-10-ATBritannia Pharmaceuticals Limited102
进行中（未招募）
1 期
Clinical trial of apomorphine subcutaneous infusion in patients with advanced Parkinson’s diseaseParkinson Disease (PD) in patients with motor fluctuations not well controlled on medical treatmentMedDRA version: 18.0Level: LLTClassification code 10034006Term: Parkinson's disease aggravatedSystem Organ Class: 100000004852EUCTR2013-000980-10-DKBritannia Pharmaceuticals Limited102
已完成
不适用
A Multi-center, Parallel-group, Double-blind, Placebo-controlled, Randomized, Ascending Dose Trial to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Infusions of OPC-108459 Administered to Subjects with Paroxysmal and Persistent Atrial Fibrillation.cardiac arrhythmiasirregular hartbeat10007521NL-OMON41577Otsuka Pharmaceutical Development & Commercialization, Inc.10
撤回
2 期
A multi-center, parallel-group, double-blind, placebo-controlled single and multiple dose escalation study to assess the safety and tolerability and the pharmacokinetic properties of SAR228810 given as IV infusion or as SC injection in patients with mild to moderate Alzheimer*s Disease.10009841Alzheimer's diseaseNL-OMON36925Sanofi-aventis5
已完成
不适用
A multi-center, parallel-group, double-blind, placebo-controlled single and multiple dose escalation study to assess the safety and tolerability and the pharmacokinetic properties of SAR228810 given as IV infusion or as SC injection in patients with mild to moderate Alzheimer*s Disease.Alzheimer's DiseaseNL-OMON38433Sanofi-aventis10